<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526004</url>
  </required_header>
  <id_info>
    <org_study_id>UCC-CFMATTERS</org_study_id>
    <nct_id>NCT02526004</nct_id>
  </id_info>
  <brief_title>Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified</brief_title>
  <acronym>CFMATTERS</acronym>
  <official_title>Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Cork</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teagasc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clininfo S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GABO:mi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Cork</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antimicrobial resistance is a significant challenge facing global healthcare. The unnecessary
      use of antibiotics is a key driver in the development of antibiotic resistance. Cystic
      Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore
      therapeutic strategies for same, as chronic lung infection overlaps with acute lung
      exacerbation's caused by a multitude of organisms. With time, chronic polymicrobial infection
      develops, with the most dominant infecting organism being Pseudomonas aeruginosa. In acute CF
      infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent
      infections and treatments result in increasing antimicrobial resistance, and alterations in
      pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing
      technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing
      our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy
      that can be compared with standard empirical antibacterial therapy currently used. Cystic
      Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results
      Stratified (CFMATTERS) will provide a randomized multi-centre controlled trial of
      microbiome-derived antimicrobial treatments versus current empirical therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage change in recovery (post-exacerbation) FEV1 relative to the previous pre-exacerbation FEV1.</measure>
    <time_frame>Time from enrollment into the study up to study close month 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to next pulmonary exacerbation</measure>
    <time_frame>Time from pulmonary exacerbation day 0, to next pulmonary exacerbation up to study close month 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement in symptom burden by day 7 as determined by Cystic Fibrosis Respiratory Symptom Diary (CFRSD)</measure>
    <time_frame>Time from pulmonary exacerbation day 0 to day 7 of pulmonary exacerbation</time_frame>
    <description>As determined by Cystic Fibrosis Respiratory Symptom Diary (CFRSD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement in health related quality of life at day 28 post treatment and at 3 months as determined by the Cystic Fibrosis Questionnaire Revised (CFQR)</measure>
    <time_frame>Time from pulmonary exacerbation day 0 to day 28 and month 3 post study treatment</time_frame>
    <description>As determined by the Cystic Fibrosis Questionnaire Revised (CFQR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of i.v. antibiotic days (home or in hospital) from time of randomisation in the trial</measure>
    <time_frame>Time from enrollment in the study up to study close month 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Time from enrollment in the study up to study close month 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of exacerbations post trial treatment</measure>
    <time_frame>Time from pulmonary exacerbation day 0 to study close month 21</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Standard Empiric Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microbiome Guided Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <arm_group_label>Standard Empiric Treatment</arm_group_label>
    <arm_group_label>Microbiome Guided Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin</intervention_name>
    <arm_group_label>Standard Empiric Treatment</arm_group_label>
    <arm_group_label>Microbiome Guided Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written and informed consent, and assent where required.

          -  Age 16 years or older at enrolment

          -  Diagnosis of CF by standard sweat test and/or genetic analysis

          -  Persistent pulmonary Pseudomonas aeruginosa colonization confirmed on at least 2
             occasions in the preceding 12 months

          -  Screening FEV1 predicted of &gt;25%

          -  Able to perform spirometry reproducibly prior to enrolment

          -  Able to expectorate and provide a sputum sample at least once daily

          -  ≥1 non-elective course of intravenous antibiotics in the preceding year

          -  Able to understand and comply with protocol requirements, restrictions and
             instructions and likely to complete the study as planned, as judged by the
             investigator

        Exclusion Criteria:

          -  Life expectancy less than 6 months

          -  They are a solid organ transplant recipient

          -  Have a requirement for immunosuppression ≥10mg corticosteroids per day

          -  Previous positive culture of non-tuberculosis mycobacteria species M.avium,
             M.abscessus or M.intracellulare within the last 12 months or undergoing active therapy

          -  Positive culture of any Burkholderia cepacia species within the last 12 months or
             undergoing active therapy

          -  Allergic bronchopulmonary aspergillosis on treatment

          -  Known allergies to more than 3 different classes of antibiotics, and intolerance or
             allergy to tobramycin.

          -  Liver portal hypertension, determined by identification of oesophageal varices

          -  Advanced kidney disease requiring a dose reduction of ceftazidime or contraindicating
             aminoglycosides

          -  History of any illness that in the opinion of the investigator, might confound the
             results of the study or pose an additional risk in administering study drug to the
             subject

          -  If patient undergoes a pulmonary exacerbation before the Microbiome analysis is
             reviewed by the Consensus Treatment Panel and i.v. antibiotics are administered. In
             this case, a repeat sputum will be sent for analysis 4 weeks after end of antibiotic
             treatment.

          -  Pregnant or breast-feeding at time of eligible pulmonary exacerbation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barry J Plant, MD</last_name>
    <email>b.plant@ucc.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph A Eustace, MD</last_name>
    <email>j.eustace@ucc.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College Cork</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry P Plant, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marcus Mall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Fajac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stuart Elborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Haworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Goss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lieven Dupont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Cork</investigator_affiliation>
    <investigator_full_name>Barry Plant</investigator_full_name>
    <investigator_title>Barry Plant, CFMATTERS Coordinator</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Stratified Antibacterial therapy</keyword>
  <keyword>Resistance</keyword>
  <keyword>Pathogen Host Interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

